ASDERA develops drugs for unmet needs 
by utilizing a patented (US Pat. 7,664,616 ) 
computational biostatistics platform to
identify complex genetic risk factors in small
(n>500) epidemiological and phase 2/3 studies.


The ASDERA time-/pipeline:

  • Validation: Confirmation of known drug targets in epilepsy
    (2013, Pharmacogenomics, in only 185 cases)
  • Proof-of-principle: L-fucose in Crohn’s disease
    (in phase 3, from 2006 dbGaP data, in only 1000 cases)
  • Current lead: Mefenamic acid against mutism in autism
    (2014, Nature: Translational Psychiatry, from 2010/12 dbGaP data, pat pending, see page AUTISM).
  • Next-in-line: a drug against metastases in breast cancer
    (2016, embargoed by NCI, from dbGaP data, pat pending).